Compare BioNano Genomics Inc (BNGO) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs T-Mobile Us Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while T-Mobile Us Inc trades at $188.72 (market cap $202.51B). The key difference: T-Mobile Us Inc is far larger — about 15341.7× BioNano Genomics Inc's market cap, and T-Mobile Us Inc pays a 2.18% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | TMUS | |
|---|---|---|
Market Cap | $13.20M | $202.51B |
Sector | Health | Media |
52-Week High | $4.92 | $259.01 |
52-Week Low | $1.09 | $167.65 |
Enterprise Value | $15.81M | $320.21B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
T-Mobile US (TMUS) trades at $188.42, up 0.43% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B and net income of $10.99B, though profit margins dipped slightly. Recent leadership changes and competitive threats from Starlink are in focus, while cash flow remains positive. The consensus price target is $243.09, implying significant upside.
Outlook remains positive given earnings beats and growth prospects, but risks include rising debt levels and satellite competition. Institutional sentiment is strongly bullish with 83% buy ratings, supporting a favorable risk-reward profile for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
